EUVIMEDEUVIMED entdecken
Open Access

Drug-resistant TB in Morobe Province, Papua New Guinea, 2012–2021

L Bumbu, S Vaccher, A Holmes, K Sodeng, S M Graham, Y D Lin

Public Health Action · 2024-12 · 14 (4) · 146-151

DOI: 10.5588/pha.24.0011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Public Health Action, online erschienen am 01.12.2024. Verfasst von L Bumbu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Angau Memorial Provincial Hospital, Morobe Provincial Health Authority, Papua New Guinea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SETTING Papua New Guinea (PNG) is a high-burden country for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). There are limited data on MDR/RR-TB notifications and treatment from the most populous province. OBJECTIVE Describe MDR/RR-TB detection and treatment outcomes in Morobe Province, the impact of the COVID-19 pandemic and factors associated with unfavourable treatment outcomes. DESIGN Retrospective cohort study of MDR/RR-TB notifications between 2012 and 2021 using routine programme registration data. Favourable outcomes were compared to unfavourable outcomes using multivariable regression. RESULTS Between 2012 and 2021, 160 cases of MDR/RR-TB were bacteriologically confirmed. Few diagnoses were made among children (2.5%), extrapulmonary cases (0.6%) or rural residents (38%). Case notifications rose sharply from 2016 after the introduction of GeneXpert to 5.6 cases per 100,000 population in 2020 before a reduction in 2021 coinciding with COVID-19 disruptions. Loss to follow-up (27.5%) and death (8.1%) were common. Unfavourable treatment outcomes were more common among male participants (aOR 3.00, 95% CI 1.38–6.45) and those treated with longer injectable-containing regimens (aOR 3.39, 95% CI 1.30–8.80). CONCLUSION MDR/RR-TB detection has increased overall, but enhanced and decentralised diagnostic capacity is needed, including in important sub-populations. Persisting low treatment success rates must be urgently addressed to minimise the further emergence of drug-resistant TB in Morobe Province.

Schlagwörter

Stichwörter der Autor:innen

Xpertloss to follow-uppulmonaryrifampicin-resistant tuberculosis

Autor:innen und Institutionen

  • Angau Memorial Provincial Hospital, Morobe Provincial Health Authority, Papua New Guinea.
  • The Burnet Institute, Melbourne, VIC, Australia.
  • University of Melbourne, Department of Paediatrics, Royal Children's Hospital, Melbourne, VIC, Australia.

Zitieren

APA

Bumbu, L., Vaccher, S., Holmes, A., Sodeng, K., Graham, S. M., & Lin, Y. D. (2024). Drug-resistant TB in Morobe Province, Papua New Guinea, 2012–2021. Public Health Action, 14(4), 146-151. https://doi.org/10.5588/pha.24.0011

Vancouver

Bumbu L, Vaccher S, Holmes A, Sodeng K, Graham SM, Lin YD. Drug-resistant TB in Morobe Province, Papua New Guinea, 2012–2021. Public Health Action. 2024;14(4):146-151. doi:10.5588/pha.24.0011

BibTeX
@article{Bumbu2024,
  author = {Bumbu, L and Vaccher, S and Holmes, A and Sodeng, K and Graham, S M and Lin, Y D},
  title = {Drug-resistant TB in Morobe Province, Papua New Guinea, 2012–2021},
  journal = {Public Health Action},
  year = {2024},
  volume = {14},
  number = {4},
  pages = {146--151},
  doi = {10.5588/pha.24.0011}
}
Kostenlos starten →